Alzamend Neuro, Inc. (ALZN) Key Metrics
ALZN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $6.3M
- Enterprise value
- $1.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.27
ALZN key metrics, FY2017–FY2026
Fiscal year ended April 30, 2026 · U.S. dollarsALZN returns How much profit the business earns on the capital it uses.
ALZN financial health Debt, liquidity and how easily interest is covered.
ALZN valuation history
ALZN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ALZN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ALZN price vs earnings per share
ALZN key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.8M | — | — | — | — | — | — | — | — | — |
| Enterprise value | $3.1M | — | — | — | — | — | — | — | — | — |
| Price / book | 5.2 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −230.6% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −212.1% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.14 | $5.94 | $63.99 | $738.45 | $1,377.00 | — | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$2.63 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$2.42 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$2.42 | — | — | — | — | — | — | — | — | — |
| Cash per share | $0.21 | — | — | — | — | — | — | — | — | — |
| Book value per share | $0.22 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $0.22 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 3.3M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −373.2% | −657.2% | — | −181.5% | −160.9% | −356.1% | −772.2% | −368.9% | −107.5% | — |
| Return on invested capital (ROIC) | — | — | — | — | — | −680.1% | −694.9% | −386.3% | −79.9% | — |
| Return on assets (ROA) | −262.6% | −172.5% | −303.9% | −145.6% | −141.9% | −213.5% | −265.2% | −248.3% | −73.1% | — |
| Return on tangible assets | −421.9% | −98.1% | — | −251.5% | −85.2% | −173.3% | −242.4% | −324.0% | −38.6% | — |
| Financial health | ||||||||||
| Total debt | — | — | $300,714 | — | — | $335,303 | $63 | $79 | — | $591,258 |
| Cash & short-term investments | $710,689 | $3.9M | $376,048 | $5.1M | $14.1M | $1.9M | $90,285 | $42,606 | $545,000 | $4,976 |
| Net debt | −$710,689 | −$3.9M | −$75,334 | −$5.1M | −$14.1M | −$1.6M | −$90,222 | −$42,527 | −$545,000 | $586,282 |
| Debt / equity | — | — | — | — | — | 0.17 | 0.00 | 0.00 | — | — |
| Debt / assets | — | — | 0.48 | — | — | 0.12 | 0.00 | 0.00 | — | 4.47 |
| Net debt / EBITDA | — | — | — | — | — | — | — | — | −74.24 | — |
| Current ratio | 1.31 | 6.58 | 0.14 | 2.03 | 12.37 | 3.24 | 1.83 | 1.27 | 24.98 | 0.08 |
| Quick ratio | 1.31 | 6.58 | 0.14 | 2.03 | 12.37 | 3.26 | 1.83 | 1.27 | 24.98 | 0.08 |
| Interest coverage | — | -249.4 | -983.8 | — | -264.8 | -31.2 | -317.7 | — | — | — |
| Working capital | $418,345 | $3.5M | −$2.8M | $3.0M | $13.2M | $2.0M | $821,709 | $316,915 | $2.3M | −$659,930 |
| Invested capital | $22,522 | $19,564 | −$2.7M | −$2.1M | −$712,300 | $418,980 | $731,487 | $274,388 | $1.8M | $1,352 |
| Tangible asset value | $733,211 | $4.0M | −$2.6M | $3.0M | $13.4M | $2.0M | $821,709 | $316,917 | $2.3M | −$584,930 |
| Net current asset value | $418,345 | $3.5M | −$2.8M | $3.0M | $13.2M | $2.0M | $821,709 | $316,917 | $2.3M | −$659,930 |
| Graham net-net per share | −$0.19 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | — | — | — | — |
| Capex / depreciation | 0.00 | 5.91 | 2.90 | 0.00 | 30.00 | 0.86 | 30.00 | 30.00 | 0.00 | 0.00 |
| Efficiency | ||||||||||
| Days payables outstanding | — | 12,803.8 | 20,843.9 | 31,909.2 | — | — | — | — | — | — |
| Receivables turnover | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | — | 0.03 | 0.02 | 0.01 | — | — | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | — | — | $105,244 | $239,816 | $354,852 | $213,026 | $1,700 |
| Average payables | $990,456 | $1.8M | $2.9M | $2.0M | $833,220 | $716,615 | $1.0M | $597,378 | $108,026 | $64,284 |
| Average inventory | — | — | — | — | — | −$16,210 | — | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ALZN's annual financial statements (latest annual report filed July 22, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ALZN valuation and financial ratios
Alzamend Neuro earned a return on equity of −373.2% in fiscal 2026.
See the ALZN income statement, the ALZN chart for price history, or the ALZN stock overview for the latest quote and news.
ALZN key metrics FAQ
What is Alzamend Neuro's return on equity?
Alzamend Neuro's return on equity (ROE) was −373.2% in fiscal 2026: net income of -$8.8 million on average shareholders' equity of $2.4 million.
What is Alzamend Neuro's free cash flow yield?
Alzamend Neuro generated -$8.1 million of free cash flow in fiscal 2026, a free cash flow yield of −212.1% on its market value at year-end ($3.8 million).
What is Alzamend Neuro's current ratio?
Alzamend Neuro's current ratio was 1.31 at the end of fiscal 2026: current assets were 1.31 times current liabilities.